Dr. David Tabatadze
MBI @ Gateway Parkwww.zatapharmaceuticals.com
ZATA is focused on two major programs:
- ZAP-D – Current blood safety approach is based on a large number of tests that do not provide 100% safety. ZAP-D (synthetic compound_ provides full safety by selective elimination of genomic molecules of the pathogens if presented in donated blood.
- ZATA’S OLIGOTHERAPEUTICS (OT). Cell membranes do not allow for the cellular uptake of negatively charged OT currently used. Low cellular penetration caused multiple OT to fail over the last couple of decades. ZATA’s technology solves this problem.
For investment or collaboration opportunity write to Dr. David Tabatadze:firstname.lastname@example.org.